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Abstract
Disease-related prion protein, PrPSc, is classically distinguished from its normal cellular precursor, PrPC, by its detergent
insolubility and partial resistance to proteolysis. Molecular diagnosis of prion disease typically relies upon detection of
protease-resistant fragments of PrPSc using proteinase K, however it is now apparent that the majority of disease-related PrP
and indeed prion infectivity may be destroyed by this treatment. Here we report that digestion of RML prion-infected
mouse brain with pronase E, followed by precipitation with sodium phosphotungstic acid, eliminates the large majority of
brain proteins, including PrPC, while preserving .70% of infectious prion titre. This procedure now allows characterization
of proteinase K-sensitive prions and investigation of their clinical relevance in human and animal prion disease without
being confounded by contaminating PrPC.
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Introduction
Prion diseases are fatal neurodegenerative conditions including
kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Stra¨ussler-
Scheinker syndrome and fatal familial insomnia in humans,
scrapie in sheep, bovine spongiform encephalopathy (BSE) in
cattle and chronic wasting disease in cervids [1–4]. They are
characterized by the post-translational conversion of host cellular
prion protein (PrPC) into an abnormal disease-related isoform
designated PrPSc [1–3,5]. According to the protein-only hypothesis
[6], an abnormal PrP isoform is the principal, if not the sole,
component of the transmissible prion [1]. It is proposed that PrPSc
is the infectious agent acting to replicate itself with high fidelity by
recruiting endogenous PrPC and that the difference between these
isoforms lies purely in the monomer conformation and its state of
aggregation [1,2,5,7,8]. The distinct clinical and neuropatholog-
ical phenotypes that distinguish prion strains are thought to be
encoded by pathogenic PrP isoforms with divergent physicochem-
ical properties [9–12].
PrPSc is extracted from affected tissue as highly aggregated
material that is not amenable to high-resolution structural
techniques. However, Fourier-transform infrared spectroscopic
methods and hydrogen/deuterium exchange have shown that
PrPSc, in sharp contrast to PrPC, has a high b-sheet content [13–
15]. PrPSc is covalently indistinguishable from PrPC [1,7,16] but
can be differentiated from PrPC by its partial resistance to
proteolysis and its marked insolubility in detergents [1,7]. Under
conditions in which PrPC exists as a detergent-soluble monomer
and is completely degraded by the non-specific protease,
proteinase K (PK), PrPSc exists in an aggregated form with the
C-terminal two thirds of the protein showing marked resistance to
proteolytic degradation leading to the generation of amino-
terminally truncated fragments of di-, mono- and non-glycosylated
PrP [1,7].
Although the molecular diagnosis of prion disease has
historically relied upon the detection of PrPSc using PK, it has
recently become apparent that PK-sensitive pathological isoforms
of PrP may play an important role in the pathogenesis of prion
diseases [17–27]. Accordingly, the development of new diagnostic
tests that do not rely on PK digestion is essential to fully
characterize human and animal prion diseases, and, in this
context, the conformation-dependent immunoassay [17,20] and
the amyloid seeding assay [27,28] both show higher diagnostic
sensitivities than can be achieved using PK. Previously, using
thermolysin and the mouse Rocky Mountain Laboratory (RML)
prion strain, we demonstrated heterogeneity among PK-sensitive
disease-related PrP isoforms and found that the majority of prion
infectivity (80%) appeared to be associated with a minor fraction of
PK-sensitive PrP [25]. Here we now report the development of a
biochemical protocol which eliminates PrPC and the majority of
brain proteins while preserving both PK-resistant and PK-sensitive
prions.
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Results
Digestion with pronase E degrades PrPC and preserves
RML prion titre
As part of ongoing research to identify proteases that offer
alternatives to PK, we and others have previously shown that
thermolysin can efficiently degrade PrPC while leaving disease-
related PrP in full length form [25,29,30]. However despite the
utility of thermolysin in certain diagnostic applications [25,29,30]
the degradation of RML prion infectivity by thermolysin obviates
its use for isolating PK-sensitive prions [25]. We have therefore
continued to examine other proteases for their ability to degrade
PrPC while preserving infectious prion titre. Of various proteases
recently investigated, pronase E was found to be the most
interesting.
Representative digestions of uninfected CD-1 and RML prion-
infected mouse brain homogenate with PK or pronase E are
shown in Figure 1. Digestion with 50 mg/ml PK at 37uC for 1 h
completely degrades PrPC in 10% (w/v) normal CD-1 brain
homogenate (Figure 1A) and in 10% (w/v) RML brain
homogenate results in a change from a mixture of full-length
and truncated PrP species to a characteristic pattern of amino-
terminally truncated fragments of di-, mono- and non-glycosylated
PrP derived from PrPSc (Figure 1A). In marked contrast, while
digestion with 100 mg/ml pronase E at 37uC for 30 min degraded
the majority of PrPC present in uninfected CD-1 brain
homogenate (Figure 1B) similar digestion of RML brain
homogenate produced no apparent change in the PrP fragment
pattern and resulted in only a modest reduction in the overall
signal intensity (Figure 1B). In this regard, the activity of pronase E
is similar to thermolysin and preserves disease-related PrP in a full
length form rather than producing the N-terminally truncated
fragments that are generated by PK.
Prior to optimizing the parameters of pronase E digestion to
completely degrade PrPC we studied what effect pronase E had on
RML infectivity using the Scrapie Cell Assay (SCA) [31]. The
SCA quantifies RML prion infectivity with an accuracy greater
than that of conventional mouse bioassay and provides the ability
to measure small percentage changes in infectious prion titre
[25,31]. Recently, we established that digestion of RML prion-
infected mouse brain homogenate with PK and thermolysin
preserves differing levels of disease-related PrP. Under optimized
conditions of proteolysis which degrade PrPC, ,85% or ,20% of
total homogenate PrP resists digestion with thermolysin or PK,
respectively [25] (Figure 2A and B). However despite this marked
disparity in the concentration of disease-related PrP, ,80% of
prion infectivity was destroyed by either enzyme [25] (Figure 2A
and B). These data show that the majority of prion infectivity in
RML brain homogenate is sensitive to these proteases and suggest
that these prions may be associated with only a minor fraction of
total homogenate PrP [25]. Remarkably, in sharp contrast to
digestion with either PK or thermolysin, we found that treatment
of RML prion-infected brain homogenate with 100 mg/ml
pronase E at 37uC did not reduce infectious prion titre even after
a 60 min digestion (Figure 2C). Prion infectivity stayed at or above
the starting titre throughout the time course, with an increase in
infectious titre reproducibly observed after 5–10 min exposure to
the protease (Figure 2C). No change in the PrP fragment pattern
was observed throughout the digestion (Figure 2C) and the overall
reduction in PrP content, to ,85% of the starting amount,
appeared to reflect the degradation of PrPC only. The physical
basis for the increase in infectious titre seen after exposure to
pronase E remains unexplained, but may reflect changes in PrP
aggregate size with concomitant alteration of specific prion
infectivity [8] or increased bioavailability of prions following
removal of other proteins.
Enrichment of PK-sensitive prions using pronase E and
sodium phosphotungstic acid precipitation
Having established that mild digestion with pronase E does not
destroy PK-sensitive prion infectivity we sought to optimize
conditions for complete digestion of residual PrPC. However this
proved to be complicated. Increasing the concentration of pronase
E to 1 mg/ml failed to completely eliminate PrPC, with ,10% of
the starting concentration remaining after 60 min of digestion time
(data not shown). The physical basis for this resistance is difficult to
interpret as this minor proportion of PrPC was readily accessible to
degradation by subsequent exposure to PK (Figure 1C). Thus this
fraction of PrPC is not trapped in an inaccessible form, for
example, in a vesicle. Resistance to digestion with pronase E may
be attributable to protection through association with other brain
proteins which are readily degraded by PK but not by pronase E.
Alternatively pronase E may reveal heterogeneity in the
aggregation state or conformation of different PrPC isoforms that
are present in normal brain as previously documented using other
methods [32–34]. Regardless of these facts, the effect of higher
concentrations of pronase E on RML infectivity was detrimental.
Exposure of RML brain homogenate to 1 mg/ml pronase E led to
a rapid decrease in prion titre over time and after a 60 min
digestion only,10% of the starting infectivity remained (Figure 3).
Figure 1. PK and pronase E digestion of mouse brain homogenate. 10% (w/v) brain homogenate from uninfected CD-1 mice (CD-1) and RML
prion-infected CD-1 mice (RML) were analysed by immunoblotting in the absence of protease digestion (2) or after digestion (+) with PK (50 mg/ml,
37uC, 1 h) (A) or pronase E (Pro) (100 mg/ml, 37uC, 30 min) (B) or after sequential digestion with pronase E (100 mg/ml, 37uC, 30 min) and PK (50 mg/
ml, 37uC, 30 min) (C). Immunoblots were probed with anti-PrP monoclonal antibody ICSM35. The blot shown in panel C has been over-exposed to
film to show residual PrPC. Apparent molecular masses are indicated in kDa.
doi:10.1371/journal.pone.0015679.g001
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Consistent with this loss of infectivity examination of digested
material by immunoblotting revealed loss of PrP signal and the
transition of PrP fragments to lower molecular mass (data not
shown). These results establish that preservation of PK-sensitive
prion infectivity is only achieved using a lower concentration
(100 mg/ml) of pronase E (Figure 2C).
Based on the foregoing results, we sought an alternative method
to remove residual PrPC from pronase E-digested brain homog-
enate. Sodium phosphotungstic acid (NaPTA) is known to
selectively precipitate both PK-resistant and PK-sensitive disease-
related PrP isoforms from detergent solubilized brain homogenate
while leaving the majority of PrPC in the soluble fraction
[17,20,25]. We therefore applied this protocol to both uninfected
CD-1 and RML prion-infected brain homogenate before or after
digestion with 100 mg/ml pronase E at 37uC for 30 min and
subsequently measured PrP concentration by ELISA or immuno-
blotting and determined prion infectivity using the SCA. These
data established that the residual PrPC that persisted in pronase E-
digested normal CD-1 brain homogenate was completely
eliminated from the NaPTA precipitated pellet fraction (Figures 4
and 5). Significantly, although the concentration of PrP in the
NaPTA pellet fraction from pronase E-digested RML brain
homogenate was reduced to ,60% of the starting level (Figure 4)
no significant variation in the fragment pattern of disease-related
PrP was observed (Figure 5) and this preparation retained .70%
of the starting infectious prion titre (Figure 4) analogous with the
levels of infectivity seen in temperature control samples that were
simply incubated sequentially at 37uC for 90 min and 20uC for
30 min (Figure 4).
Our findings show that mild digestion with pronase E followed
by detergent solubilisation and NaPTA precipitation produces a
brain fraction devoid of PrPC that contains .70% of prion
infectivity. To assess the relative degree of enrichment of prions
achieved by this protocol, we performed SDS-PAGE of treated
samples and used silver stain to visualize total protein. This
analysis revealed that although pronase E digestion or NaPTA
Figure 2. RML prion infectivity and PrP content following digestion with PK, thermolysin or pronase E. 10% (w/v) RML prion-infected
brain homogenate was incubated at 37uC with (A) PK (50 mg/ml); (B) thermolysin (100 mg/ml) or (C) pronase E (100 mg/ml) for varying incubation
times. For each time point, PrP (filled circles) was measured by ELISA and expressed as a percentage of total PrP present in the untreated sample;
mean6 S.E.M. (n=3, PK and thermolysin; n=5, pronase E). RML prion infectivity (open circles) was measured by the Scrapie Cell Assay and expressed
as a percentage of total infectivity present in the untreated sample; mean 6 S.E.M. (n=3, PK and thermolysin; n= 5, pronase E). Immunoblots of the
corresponding protease and incubation time point are shown in panels to the right. Blots were probed with anti-PrP monoclonal antibody ICSM35.
Apparent molecular masses are shown in kDa. Data in panels A and B have been published previously [25].
doi:10.1371/journal.pone.0015679.g002
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precipitation alone were relatively ineffective in removing brain
proteins, when applied in combination a considerable purification
of prions (,150 fold) was achieved with respect to total protein
(Figure 6).
Discussion
Mammalian prions are hypothesized to be self-propagating
fibrillar or amyloid forms of PrP in which the ends of the
propagating fibrils constitute the infectious entity and that the
exponential rise in prion titre during disease progression is a
consequence of fiber fragmentation [5,35,36]. However, prion
diseased brain contains a highly heterogeneous population of
abnormal PrP isoforms that may differ with respect to their
conformation, aggregate size, potential neurotoxicity and specific
prion infectivity [5] and indeed prion strains, rather than
constituting a molecular clone, appear to comprise an ensemble
or quasispecies maintained under host selection pressure [5,37].
Due to this heterogeneity, the precise structure of the infectious
particle remains unclear. To date, the most highly enriched
preparations contain a large molar excess of PrP per infectious unit
[8,38] and it remains unclear what proportion of PrP species are
actually infectious [8]. Understanding the ratio of PrP molecules to
infectivity is highly convoluted however because of rapid clearance
of prions from the brain following intra-cerebral challenge [38]
and possible differential clearance kinetics of different size
particles. A major confounding issue in this regard is the growing
realization that the pathogenesis of both human and animal prion
diseases involves the propagation of protease-sensitive disease-
related isoforms of PrP [17–27] and that a substantial fraction of
prion infectivity may be readily sensitive to protease degradation
[25]. Indeed, in multiple prion strain/host combinations it now
appears that the majority of disease-related PrP may be destroyed
by PK under conditions that are typically employed to detect
prototypical PrPSc [20,23,25]. PK-sensitive, disease-related, forms
of PrP have, to date, been demonstrated by conformation
dependent immunoassay [17,20,23,39], by immunoblotting fol-
lowing biochemical purification [18,40], cold PK digestion [19],
immunological capture [21] or limited digestion with thermolysin
[25]. However, a simple protocol for isolating PK-sensitive
abnormal PrP isoforms in the absence of contaminating PrPC
without severely affecting prion titre has not been described. Here
we demonstrate that limited digestion of brain homogenate with
pronase E followed by detergent solubilisation and selective
precipitation with NaPTA yields a preparation that retains the
majority of the infectious prion titre but is devoid of PrPC and the
majority of other brain proteins. It is envisaged that this protocol
may have widespread utility in improving diagnostic sensitivity
from analysis of brain and other tissues in human and animal
prion diseases and may now also simplify isolation and biophysical
characterization of PrP structures having the highest specific prion
infectivity. Methods for isolating slowly sedimenting, low density
PrPSc aggregates of high specific prion infectivity from different
prion strains have recently been described [41] however the
authors reported that an abundance of PrPC and other
components in these slowly sedimenting fractions prevented
detailed characterization of the most infectious PrP particles.
Similar comparative fractionation of pronase E and NaPTA
precipitated samples before or after PK digestion would now be
Figure 3. RML prion infectivity following digestion with 1 mg/
ml pronase E. 10% (w/v) RML brain homogenate was incubated with
pronase E (1 mg/ml at 37uC) for varying incubation times. For each time
point RML prion infectivity was measured by the Scrapie Cell Assay and
expressed as a percentage of total infectivity present in the untreated
sample; mean 6 S.E.M. (n=5).
doi:10.1371/journal.pone.0015679.g003
Figure 4. Pronase E-resistant RML prion infectivity is precipi-
tated by NaPTA. 10% (w/v) homogenates from normal CD-1 brain
(CD-1, white bars) or RML prion-infected brain (RML, black bars) were
either untreated (whole homogenate), incubated at 37uC for 90 min
and 20uC for 30 min (temperature control), digested with pronase E at
100 mg/ml, 37uC for 30 min (pronase), precipitated by NaPTA (NaPTA) or
sequentially digested by pronase E at 100 mg/ml, 37uC for 30 min and
precipitated by NaPTA (pronase + NaPTA). The concentration of PrP in
all samples was measured by ELISA (A) and is expressed as a percentage
of the total PrP present in the untreated RML samples; mean 6 S.E.M.
(n= 5). RML prion infectivity was measured by the Scrapie Cell Assay (B)
and expressed as total infectivity present in the samples; mean 6 S.E.M.
(n= 5).
doi:10.1371/journal.pone.0015679.g004
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expected to inform upon the density distribution of both PK-
sensitive and PK-resistant abnormal PrP species and enable
measurement of specific prion infectivity without being confound-
ed by contaminating PrPC. Further biophysical characterization of
slowly sedimenting PK-sensitive abnormal PrP species may reveal
whether these are predominantly composed of small PrP oligomers
or larger PrP aggregates associated with lipid.
Materials and Methods
Ethics Statement
Work with animals was performed under licence granted by the
UK Home Office (Project Licence number 70/6454) and
conformed to University College London institutional guidelines.
Prion-infected tissues
All procedures were carried out in a microbiological contain-
ment level 3 facility with strict adherence to safety protocols.
Brains from 400 terminally-affected CD-1 mice infected with the
RML prion strain [42] were homogenized in Dulbecco’s
phosphate buffered saline lacking Ca2+ or Mg2+ ions (D-PBS)
using tissue grinders to produce two pools of 10% (w/v) RML
brain homogenate (designated I6200 and I8700). Both I6200 and
I8700 showed comparable prion infectivity titres in the Scrapie
Cell Assay (SCA) [25,31] and the titre of I6200 measured by
bioassay in CD-1 mice was 109.3 intracerebral LD50 units/g of
brain [25]. Three batches of 18 brains from uninfected CD-1 mice
were homogenized to produce three pools of,90 ml of 10% (w/v)
normal CD-1 brain homogenate (designated I7219, I8402 or
I10340). Pooled homogenates were dispensed as aliquots and
stored at 270uC until use.
Enzymatic digestion
Protease type XIV (synonyms: pronase E, actinase E) from
Streptomyces griseus was obtained as a lyophilized powder from
Sigma-Aldrich (Prod. No. P5147). The specific enzymatic activity
is approx 4 units/mg (where 1 unit liberates 1.0 mmol of tyrosine/
min at pH 7.5 at 37uC using casein as a substrate). Proteinase K
(EC 3.4.21.64) from Tritirachium album limber was obtained freeze-
dried from Merck. The specific enzymatic activity is approx 30
Anson units/g (where 1 Anson unit is the amount of enzyme that
liberates 1 mmol of Folin-positive amino acids/min at pH 7.5 and
35uC, using haemoglobin as a substrate). Thermolysin (EC
3.4.24.27) from Bacillus thermoproteolyticus rokko was obtained
freeze-dried from Sigma–Aldrich. The specific enzymatic activity
is 50–100 units/mg of protein (where 1 unit liberates 1 mmol of
tyrosine/min at pH 7.5 and 37uC using casein as a substrate).
Stock solutions of 1 mg/ml thermolysin and PK and 1 mg/ml and
10 mg/ml pronase E were prepared in water and aliquots were
stored at 270uC. Aliquots of 10% (w/v) brain homogenates in D-
PBS were digested for variable time periods at 37uC with
thermolysin (at a final protease concentration of 100 mg/ml), with
PK (at a final protease concentration of 50 mg/ml) or with pronase
E (at final protease concentrations varying between 100 mg/ml to
1 mg/ml). Aliquots of the digested brain homogenates or
untreated control samples were snap-frozen in liquid nitrogen
for infectivity studies, or processed immediately for analysis by
either immunoblotting or ELISA.
PrP immunoblotting
Aliquots of brain homogenate were mixed with an equal volume
of 2 x SDS sample buffer (125 mM Tris/HCl (pH 6.8), 20% (v/v)
glycerol, 4% (w/v) SDS, 4% (v/v) 2-mercaptoethanol and 0.02%
(w/v) bromophenol blue containing 8 mM 4-(2-aminoethyl)
benzenesulphonyl fluoride) and immediately transferred to a
100uC heating block for 10 min. Samples were analysed by
electrophoresis in 16% (w/v) Tris-glycine gels and immunoblotting
as described previously [43]. Blots were blocked in PBS containing
0.05% (v/v) Tween 20 (PBST) and 5% (w/v) non-fat dried
skimmed milk powder and probed with the anti-PrP monoclonal
antibody ICSM 35 (D-Gen Ltd, London) at 0.2 mg/ml final
antibody concentration in PBST. Blots were developed using
alkaline-phosphatase-conjugated anti-mouse IgG secondary anti-
body and chemiluminescent substrate CDP-Star (Tropix), and
visualized on BiomaxMR film (Kodak) as described previously
[43].
Figure 5. Immunoblot analysis of pronase E digested and
NaPTA precipitated mouse brain homogenate. 10% (w/v)
homogenates from normal CD-1 brain (CD-1) or RML prion-infected
brain (RML) were either untreated (Pro 2, NaPTA 2), digested by
pronase E at 100 mg/ml, 37uC for 30 min (Pro +, NaPTA 2), precipitated
by NaPTA (Pro 2, NaPTA +) or sequentially digested by pronase at
100 mg/ml, 37uC for 30 min and precipitated by NaPTA (Pro +, NaPTA +).
Equivalent aliquots of each sample were analysed by immunoblotting
using anti-PrP monoclonal antibody ICSM35. Apparent molecular
masses are indicated in kDa.
doi:10.1371/journal.pone.0015679.g005
Figure 6. Pronase E digested and NaPTA precipitated mouse
brain homogenate evaluated by silver stain SDS-PAGE. 10% (w/
v) homogenates from normal CD-1 brain (CD-1) or RML prion-infected
brain (RML) were either untreated (Pro 2, NaPTA 2), digested by
pronase E at 100 mg/ml, 37uC for 30 min (Pro +, NaPTA 2), precipitated
by NaPTA (Pro 2, NaPTA +) or sequentially digested by pronase E at
100 mg/ml, 37uC for 30 min and precipitated by NaPTA (Pro +, NaPTA +).
The equivalent of 2 ml 10% (w/v) brain homogenate was loaded in each
lane and the gel was stained with silver nitrate.
doi:10.1371/journal.pone.0015679.g006
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Silver staining
SDS-PAGE gels were fixed in 40% (v/v) ethanol and 10% (v/v)
glacial acetic acid before silver staining using the PlusOne silver
stain kit (GE Healthcare, Little Chalfont, UK) according to the
manufacturers instructions. Gels were photographed on a light
box using a camera stand (Kaiser RS-1) and a Nikon D80 with
18–135 mm zoom lens or a Nikon Coolpix P6000.
ELISA
Methods were performed as described previously [44] with
adaptations. Brain homogenates were treated at 37uC with
thermolysin (100 mg/ml final protease concentration), PK
(50 mg/ml final protease concentration) or pronase E (100 mg/ml
or 1 mg/ml final protease concentrations) for a range of
incubation times. Subsequently, 10 ml aliquots of these samples
or untreated brain homogenate and temperature controls were
adjusted with 10 ml of 4% (w/v) SDS and heated at 100uC for
10 min. Samples were centrifuged at 1006g for 30 seconds before
addition of 600 ml of 50 mM Tris/HCl (pH 8.4) containing 2%
(v/v) Triton X-100, 2% (w/v) sodium lauroylsarcosine and 2%
(w/v) bovine serum albumin (Fraction V, protease free, Sigma–
Aldrich). Aliquots (50 ml) were transferred into the wells of
microtitre plates (Microlon 96W, Greiner Bio-One) containing
immobilized anti-PrP monoclonal antibody ICSM18 (250 ng/
well; D-Gen Ltd, London). After incubation at 37uC for 1 hr with
constant agitation, wells were washed with 36300 ml of PBST
using an automated microplate washer, followed by the addition of
100 ml of PBS containing 1% (v/v) Tween 20 and 1 mg/ml
biotinylated anti-PrP monoclonal antibody ICSM 35. Following
incubation at 37uC for 1 h with constant agitation, wells were
washed as detailed above, followed by the addition of 100 ml of
PBS containing 1% (v/v) Tween 20 and a dilution of streptavidin–
horseradish-peroxidase conjugate (1:10000 dilution; Dako). After
incubation at 37uC for 30 min with constant agitation, wells were
washed with 46300 ml of PBST. Wells were developed with 100 ml
of QuantaBlu working solution (Pierce) and the reactions were
stopped by the addition of 100 ml of QuantaBlu stop solution
(Pierce). Fluorescence (lex = 340 nm, lem =420 nm) was
measured on a Tecan spectra image microplate reader.
Sodium phosphotungstic acid (NaPTA) precipitation
The use of NaPTA was adapted from Safar and colleagues [17]
as described previously [43]. Briefly, 50 ml aliquots of 10% (w/v)
brain homogenate were incubated at 37uC for 30 min in the
absence or presence of pronase E (100 mg/ml final concentration).
Pronase E digestion was stopped by the addition of 1 ml 0.5 M
EDTA pH 8.0 prepared in water. Samples were incubated with
50 ml D-PBS containing 4% (w/v) sodium lauroylsarcosine
(sarkosyl) at 37uC for 30 min with constant agitation. Samples
were subsequently adjusted with 8.5 ml of a stock solution of 4%
(w/v) NaPTA prepared in water and adjusted to pH 7.4
(magnesium chloride was omitted) to give a final concentration
in the sample of 0.3% (w/v). Samples were incubated at 37uC for
30 min with constant agitation before centrifugation at 16,1006g
for 30 min in a microfuge. After careful isolation of the
supernatant, the pellets were resuspended to 50 ml with D-PBS
containing 0.1% (w/v) sarkosyl. Aliquots of the resuspended pellets
were snap-frozen in liquid nitrogen for infectivity studies, or
processed immediately for analysis by either immunoblotting or
ELISA.
Scrapie cell assay
High-sensitivity cell-culture assays for RML prion infectivity
were performed as described previously [25,31]. Briefly, PK1 cells,
an N2a sub-clone highly susceptible to infection with RML prions,
were exposed for 3 days in 96-well plates to serial dilutions (1024
and 1025) of 10% (w/v) RML brain homogenate before or after
protease digestion or precipitation with NaPTA. Serial dilution of
untreated 10% (w/v) RML brain homogenate (361024 to
161026) of known infectivity titre was performed in parallel.
The prion infectivity titre in experimental samples was deduced
from the reference preparation [31].
Statistical analysis
All experiments were conducted at least three times. Figures
show representative data and means 6 S.E.M.
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